10Oct 2024
RAAS Inhibitors and Bone Health: No Significant Link Found

RAAS Inhibitors and Bone Health: No Significant Link Found

The study analyzed data from 1,625 hypertensive patients aged 40–75 years from the Risk Evaluation of Cancers in Chinese Diabetic Individuals (REACTION) study to evaluate the impact of renin-angiotensin-aldosterone system (RAAS) inhibitors on bone health. The cross-sectional analysis showed no significant association between the use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) and osteoporosis or fracture risk. Over a mean follow-up of 3.4 years, 478 new osteoporosis cases and 76 fractures were identified, with hazard ratios (HRs) for osteoporosis of 1.005 and 1.077 for ACEI and ARB users, respectively (p > 0.05). Additionally, the duration of RAAS inhibitor use did not correlate with osteoporosis risk or improvement.

  • #orthopaedics

Like

Save

Share